/
We are a biotechnology company, leveraging our proprietary cell expansion platform to develop scalable, cell-based solutions across the healthcare, food, and agriculture sectors. Through a collaborative network of ventures, we are advancing a diverse pipeline of products and services, including cultivated food, regenerative medicine, and cell-based ingredients.
The business is unprofitable at the operating level (-1659.88% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 309.8% YoY with margins expanding 5137.1pp.
ROIC dropped from -137.77% to -281.61%, capital efficiency is deteriorating. Negative free cash flow of -$20M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$1M
▲ +309.8% YoY
Net Income (TTM)
-$26M
▼ -8.1% YoY
Op. Margin
-2410.84%
▲ +5137.1pp YoY
ROIC
-309.81%
▼ -143.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$22M
▼ -8.1% YoY
Op. Cash Flow (TTM)
-$20M
▼ -1.1% YoY
Net Debt
$3M
Cash & Equiv.
$3M
5Y CAGR: +90.0%
Continue Research